Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > When is antibody testing done and why is it important?
View:
Post by Gbathat on Apr 24, 2021 6:05pm

When is antibody testing done and why is it important?

https://www.mayoclinic.org/diseases-conditions/coronavirus/expert-answers/covid-antibody-tests/faq-20484429 

When is antibody testing done and why is it important?

Antibody testing, also known as serology testing, is usually done after full recovery from COVID-19. Eligibility may vary, depending on the availability of tests. A health care professional takes a blood sample, usually by a finger p*ick or by drawing blood from a vein in the arm. Then the sample is tested to determine whether you've developed antibodies against the virus. The immune system produces these antibodies — proteins that are critical for fighting and clearing out the virus.

If test results show that you have antibodies, it indicates that you were likely infected with COVID-19 at some time in the past. It may also mean that you have some immunity. But there's a lack of evidence on whether having antibodies means you're protected against reinfection with COVID-19. The level of immunity and how long immunity lasts are not yet known. Ongoing studies will eventually reveal more data on this.

The timing and type of antibody test affects accuracy. If you have testing too early in the course of infection, when the immune response is still building up in your body, the test may not detect antibodies. So antibody testing is not recommended until at least 14 days after the onset of symptoms. The U.S. Food and Drug Administration (FDA) authorized specific antibody tests, but tests with questionable accuracy are still on the market.

Another benefit of accurate antibody testing is that people who've recovered from COVID-19 may be eligible to donate plasma, a part of their blood. This plasma could be used to treat others with severe disease and boost the ability to fight the virus. Doctors call this convalescent plasma.

Comment by DavidKingCanada on Apr 25, 2021 1:02am
I still believe regardless of the FDAs approval of Aducanumab PMN will continue to strive forward. Long term Buy and Hold. Keep in mind, the Debentures expire in 2026. Chances are in 5 Years the Share Price will be much higher. 
Comment by Gbathat on Apr 25, 2021 8:54am
Agreed.  I think there is enough clinical trial data from other drugs targeting amyloid beta that support the hypothesis.  Aducanumab would be a table setter for PMN310. I am very optimistic about PMN310.  The paper on antibody down selection that I shared recently was encouraging in that their down-selection process was based on nine or so factors that are expected to lead to ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities